Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Akari Therapeutics ( (AKTX) ).
Akari Therapeutics successfully completed the issuance of unsecured promissory notes in a private placement, known as the August 2025 Notes Offering, with a total principal amount of approximately $3.8 million. The final tranche of this offering was closed on September 26, 2025, with the company issuing $312,500 in notes for a purchase price of $250,000, marking the completion of the $3 million aggregate purchase price goal.
The most recent analyst rating on (AKTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.
Spark’s Take on AKTX Stock
According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.
Akari Therapeutics’ stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company’s speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.
To see Spark’s full report on AKTX stock, click here.
More about Akari Therapeutics
Average Trading Volume: 177,040
Technical Sentiment Signal: Sell
Current Market Cap: $31.64M
See more data about AKTX stock on TipRanks’ Stock Analysis page.